EBV-specific immune effector cell therapy for pre-emptive treatment of EBV-associated lymphoproliferative disease and PTLD

Phase 2, open-label, single-arm trial of EBV-specific immune effector cells in EBV-positive lymphoproliferative disorder (EBV-LPD), Post-Transplant Lymphoproliferative Disorder (PTLD) and Epstein-Barr virus infection, sponsored by Vectorite Biomedical Inc. Primary endpoints: Immediate clinical response after infusion at year 1 and EBV viral titre or DNA copy number at year 1. Started May 2009; status: completed.